Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Breathtec Biomedical Inc
I hear rumblings amongst brokers in Vancouver that Breathtec should be trading in Late October..allot of excitement on that one. Breathtec will further breath testing in the field of disease detection with a focus on lung cancer to start.
Also looks like they are considering alzheimers detection..Alzheimers is huge problem in our society and a hand held breath test for early detection would be very disruptive technology in this field.
Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors.
Tisch U1, Schlesinger I, Ionescu R, Nassar M, Axelrod N, Robertman D, Tessler Y, Azar F, Marmur A, Aharon-Peretz J, Haick H.
Author information
Abstract
AIM:
To study the feasibility of a novel method in nanomedicine that is based on breath testing for identifying Alzheimer's disease (AD) and Parkinson's disease (PD), as representative examples of neurodegenerative conditions.
PATIENTS & METHODS:
Alveolar breath was collected from 57 volunteers (AD patients, PD patients and healthy controls) and analyzed using combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles). Discriminant factor analysis was applied to detect statistically significant differences between study groups and classification success was estimated using cross-validation. The pattern identification was supported by chemical analysis of the breath samples using gas chromatography combined with mass spectrometry.
RESULTS:
The combinations of sensors could clearly distinguish AD from healthy states, PD from healthy states, and AD from PD states, with a classification accuracy of 85, 78 and 84%, respectively. Gas chromatography combined with mass spectrometry analysis showed statistically significant differences in the average abundance of several volatile organic compounds in the breath of AD, PD and healthy subjects, thus supporting the breath prints observed with the sensors.
CONCLUSION:
The breath prints that were identified with combinations of nanomaterial-based sensors have future potential as cost-effective, fast and reliable biomarkers for AD and PD.
BREATHTEC CANNABIX
I see no issues with the way Cannabix has been run. They have acquired a guru in Dr Rick Yost to work on the mass spectrometer aspect of a breathalyzer for very reasonable money. That was with help of Breathtec and no cost to BLO. They have hired a great guy in Jared Boock to ensure the University program is carried out in a quick way. They have enough cash in the bank to focus on this device.
Breathtec is doing their thing in disease detection. That will take millions and BLO could not afford to dilute shareholders by trying to do THC AND diseases..they would have had to raise $3-5M in cash to be able to do both things just to get started on diseases
Both companies have been funded to develop breath testing technology that is similar. They are separately funded and do not take anything away from each other. They develop the breath testing aspect together.
I am not sure what investors concerns here are about Breathtec. Blo is not funding Breathtec for any money but has benefitted from Breathtec's work with the UFL and introduction of Dr Yost to BLO
I believe Breathtec is going public with a merger with PBA company spinout. They had to do a three way amalgamation. I have heard Breathtec has completed close to $3M in funding and will be listing the PBA spinout soon.
I feel positive that this group is working with the right people and has demonstrated the ability to raise the required cash at the right times. Many companies are cash starved but this group has been able to secure funding for both BLO and Cannabix at reasonable prices without dilution.
They are not the typical OTC promoters who issue frivolous news releases. They are working on getting a working device together and don't have huge salaries or fancy offices. Their lab work is done at UFL world class lab by Phd Jared Boock and Dr Rick Yosts team. The work being done is world class. Be patient and I believe you will be rewarded. This technology is in its earliest stage and will take time to develop.. but BLO is ahead of the world and has the right people on it and is spending their money on product rather then promotion or fancy offices or huge salaries.
Who is Anthony Cataldo? Wat doe he have to do with the market on the breathalyzer industry>
Its like that joke who lead Buzzfeed to ratifies BLO.
Anthony Cataldo?,,,,who and why is he good for a company thats spending money on developing a device? Should they pay this guy money to promote the company.....I googled Anthony Cataldo and fid no credibility...
AGILENT now sells of $1B a year of Rick Yost's developed mass spectrometer.
http://www.agilent.com/about/newsroom/lsca/mediakit/asms2014/ASMS_2014_Saturday_Night_Event.pdf
https://www.msacl.org/index.php?header=MSACL_2015_US&tab=Details&subtab=Plenary_Lectures
Innovations for Translating Metabolomics into the Clinical Laboratory
Rick Yost
University of Florida
Translating rapid advances in mass spectrometry and metabolomics into the clinical laboratory portends major changes in clinical analysis. Innovations in mass spectrometry, including ion mobility and FAIMS, ambient ionization, imaging mass spectrometry and global metabolomics all offer the opportunity for developing more sensitive, selective and rapid methods for the clinical laboratory. This lecture will include a perspective on the changing landscape for mass spectrometry in the clinical laboratory, insights into instrumental innovations, and examples of clinical applications.
Rick Yost is a GURU is mass spectrometry and FAIMS.
The Yost Research Group is developing and evaluating high-field asymmetric waveform ion mobility spectrometry (FAIMS) coupled to a mass spectrometer for the analysis of various compound classes including THC. Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has led to the publication of over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.[color=red][/color]
- See more at: http://thenewswire.ca/archives?tnwcatalyst2=release_id%3D17087#sthash.u05tv3eY.dpuf
One of the most popular types of tandem MS instrument is the triple quadrupole mass spectrometer, invented at Michigan State University by Richard A. Yost (now a chemistry professor at the University of Florida, Gainesville) and chemistry professor Christie G. Enke (now at the University of New Mexico, Albuquerque). James D. Morrison of Latrobe University, Melbourne, Australia, helped Yost and Enke reduce the technique to practice. Tandem MS “was really popularized by triple-stage quadrupoles introduced first by Finnigan and Sciex (in 1980), followed by Extranuclear and Nermag, and some time later by VG,” says Michael S. Story of ThermoQuest Corp., San Jose, Calif.
There are only three companies in the Thc breathalyzer field. BLO is one and LCTC is another and the Washington State people are the other.
BLOZF is small and very quick to adapt its technology. I think they will be the first mover in the field. They have a product which is being tested, nut I hear they are also working on other tecnoolgies to deliver a roadside device.
I am invested in BLO as they have money and the ability to source experts to help them to be first in the field Even if the first device does not work, they will achieve a device that works by patterning with experts in the fields
My rationale for participating in this company as an investor is straightforward:
If it works, it will be huge. If it doesn’t, then I take that risk willingly and on a calculated basis, knowing I could lose my money. But it’s the possibility this company represents that excites me, albeit cautiously so.
Police need a tool that is similar to the breath test for alcohol. It will be limited to gathering evidence that can ONLY BE RELATED TO IMPAIRED DRIVING. Oral swabs give evidence of DNA that the general public needs to be protected from.
Police in the US have a lack of credibility over the last year.. The Legal system is in dire needs of breath test for THC impairment. BLOZF is working on getting that out. Lifeloc is another company trying to do it but they are valued at over $200M. BLOZF is valued at around $15M....the upside on BLOZF is MONSTROUS if they get this done....but its a risk reward scenario.
US POLICE PUBLIC RELATIONS:
A wave of peaceful protests, aimed at denouncing police violence, swept across the US on Saturday, with the number of protesters peaking in Los Angeles, where there were over 5,000 in the “Millions March for First Amendment Rights.”
“Hands up, don’t shoot”, “Black lives matter” and “No justice, no peace,” – these mottos united demonstrations that took place in several major American cities – Los Angeles, New York and Ferguson, where there have been several cases of fatal shooting by the police.
The protesters were calling for justice for those killed by police – Michael Brown (Ferguson) and Eric Garner (New York), as well as Ezell Ford and Omar Abrego (both from Los Angeles) among them.
Denver Show summary:
MEDICAL PROTOTYPE DEVELOPMENT.
I hope people will research before they panic dump this to the SHARKS
How to Develop a Successful Prototype
http://www.emdt.co.uk/daily-buzz/how-develop-successful-prototype
Posted in Design Services by Thomas Klein on September 17, 2014
Engineering prototypes are important to mitigate the risks of the development process of a medical device. Here is an overview of the different prototypes and their function in the development pathway.
Thomas Klein
Source: eg technology
It can be a long and costly process to bring a medical device to market. Along the way, there are many things that can go wrong: The technology doesn’t work as planned, the device fails the clinical tests, the product can’t be manufactured in a feasible way, or the reimbursement pathway is not clearly defined. Therefore, engineering prototypes are an essential tool to mitigate those risks and avoid potential pitfalls. At this year’s MEDTEC Ireland, Lucy Malby, business development manager at engineering consultancy eg technology will provide some insights on how to develop and design a successful prototype.
According to Malby, the development pathway consists of “taking an idea through a number of prototypes, each of which comes closer and closer to the production unit, until you have something that you can use to complete your regulatory submission.”
“For a medical device the first thing that needs to happen is a concept and definition phase. All the stakeholders and partners need to understand what the objective of the development is,” Malby told EMDT. “You need to write down the specifications and complete some conception work to make sure that what you take forward into a prototype is exactly what everyone is agreed upon. At that stage, you should have a draft specification stating ‘This is what it might look like, this is what it needs to do and this is the way that it could be achieved.’”
After that, companies need to generate a prototype. There are a number of different engineering prototypes, each of which has a specific function in the development pathway:
The Proof-of-Principle Prototype is designed to test the validity of a particular design approach.
The Breadboard is an early functional prototype to assess an aspect of the device such as the initial electronics lay-out or optics pathway.
The Alpha Prototype is an intermediate version designed to demonstrate the functions of a device. The insights gained through constructive Design Review can be used to refine the technology and design.
The Beta Prototype is designed to further demonstrate the functions of a product. It should look like and work like the final product, but will not be produced using the factory manufacturing process.
A Pre-Production Prototype should look very much like the final device and is generated to confirm whether the production design meets the product requirements specification and if it can be produced efficiently by the manufacturer. It will typically be generated with parts made off-tool and in accordance with the relevant production process for that part.
The Production Design is the final output from the Transfer to Manufacture phase of the design process. It will specify the manufacturing and assembly methods and materials suitable for the expected production quantities. The manufacturer will use the production design to validate the product requirements and specifications.
Finally, the manufacturer produces a small batch of the device in accordance with the chosen manufacturing method as the Pilot Production batch.
According to Malby, the number of prototypes that a company needs depends entirely on the type of device, its size, complexity, and the manufacturing technique. In addition to being milestones in the design process, prototypes should be used for clinical trials and to confront the market with the device to assess whether end users (be they hospitals, reimbursement payers or patients) are willing to pay for such a product. The earlier companies can get that feedback from the market, the easier it can make the adjustments necessary to meet the expectations of the final customers.
In order to make sure that the feedback of each development loop is taken into consideration, Malby advises companies to divide the development process into clear phases and to systematically incorporate what they learned in the last phase into the next one.
As most engineers are probably never entirely content with their designs (there is always something to improve and to refine) companies should make sure that they don’t miss the right time to bring a product to market. “They should stop developing when a design is fit for purpose, meets the market needs and will provide a revenue stream. This provides the commercial freedom to develop updates and generation two product.” Malby says.
WIKIPEDIA ON DESCRIPTION OF PROTOTYPE:
http://en.wikipedia.org/wiki/Prototype
Review the description of PROTTYPE and consider for yourself where BLOZF is in the development of a new technology.
A prototype is an early sample, model, or release of a product built to test a concept or process or to act as a thing to be replicated or learned from. It is a term used in a variety of contexts, including semantics, design, electronics, and software programming. A prototype is designed to test and try a new design to enhance precision by system analysts and users. Prototyping serves to provide specifications for a real, working system rather than a theoretical one.[1] In some workflow models, creating a prototype (a process sometimes called materialization) is the step between the formalization and the evaluation of an idea.[2]
There is no general agreement on what constitutes a "prototype" and the word is often used interchangeably with the word "model" which can cause confusion. In general, "prototypes" fall into two basic categories:
Proof-of-Principle Prototype (Model) (in electronics sometimes built on a breadboard). A Proof of concept prototype is used to test some aspect(s) of the intended design without attempting to exactly simulate the visual appearance, choice of materials or intended manufacturing process. Such prototypes can be used to "prove" out a potential design approach, such as range of motion, mechanics, sensors, architecture, etc. These types of models are often used to identify which design options will not work, or where further development and testing is necessary.
Form Study Prototype (Model). This type of prototype will allow designers to explore the basic size, look and feel of a product without simulating the actual function or exact visual appearance of the product. They can help assess ergonomic factors and provide insight into visual aspects of the product's final form.
What is the difference between an alpha and a beta version of a prototype?
http://www.quora.com/What-is-the-difference-between-an-alpha-and-a-beta-version-of-a-prototype
Prototype: Is designed to effectively communicating the core features or benefits to potential users or other stakeholders (e.g. investors or developers). It can be done in something as simple as Balsamiq or even paper and really is to visualize the main things people will be able to DO with the tool as a way of helping stakeholders to attach the solution to problem you are solving.
Alpha: Is a coded version of the key features of the solution that will give people a chance to actually interact with proposed solution. It's critical as there is always risk that the 'I like the sound of this' to 'actually, this doesnt make any sense' will happen at this stage and you want to get to that point with minimal development. Alpha versions can often be done using more interactive wireframing tools that can even be pulled into code later on. Any competent team with conviction for what they are doing however will code an Alpha as the basis for what will become the actual product. Often an Alpha will be used to also identify and/or resolve any key technical challenges expected in the development.
Beta: A coded and more polished version of the key features of the solution that could be used directly by a third party audience with the intent to PROVE that people actually want the solution and also to gather additional data relating to usage to be able to support future investment and what should be developed or changed next. They can be run privately (hidden or limited/handpicked set of people). This is usually when there is risks, unknowns or a likelihood of things breaking and you dont want to ruin your brand. Public betas are usually more about setting the right expectations with users. 'Yes, we know that feature would be a good ideas, we're working on it' .. or 'Hey, try it.. BUT you should expect to hit issues cause it's just been released so don't get all uppity if/when you do'
FOLKS....WHEN INVESTING IN THIS TECHNOLOGY. investors have to be cognizant that it is a development of technology that so far has been academically tested. BLOZF has never claimed that it was more then that. They have funded its development and worked with experts. It is not something that simply gets produced like a mechanical tool.
I believe they have a prototype and the prototype needs to be advanced to be accurate as law enforcement will need 100% certainity. If BLOZF were to demonstrate a few positive results and pump the stock on that basis and the subsequent third party testing fails..then investors would accuse management of fraud etc. They have to be 100% accurate. They have not PUMPED...nor dumped this stock. Any claims of fraud to this point has no merit as the company has not made any claims that they cannot stand 100% behind.
The Buzzfeeded article is written on behalf of Brochstein and by an unknown reporter of unknown credibility..you can't base your investing decision on this one article alone.
Articles points of Interest:
]Huestis also expressed serious reservations about the possibility of a marijuana breathalyzer hitting your local DUI checkpoint anytime soon. While research shows traces of cannabis will stay in the breath for two hours at most, the high can last much longer for some people, and even finding those traces can require precise instrumentation that is difficult to put in a portable device. Cannabix is basing their prototypes off of research done by Olof Beck, an adjunct professor in clinical pharmacology at the Karolinska Institute, a medical school in Sweden. But Huestis said that her own research on THC concentrations in breath was not matching up with Beck’s, so she set out to figure out where the discrepancy was. When she visited his lab to see how he was able to determine recent marijuana use from breath alone, she discovered that most of his breath samples were contaminated with saliva, which retains higher concentrations of THC for much longer than breath does.
WOULD ONE SCIENTIST ACCUSE ANOTHER COLLEAGUE OF BEING INEPT LIKE BUZZED CLAIMS HUESTIS HAS. THIS WOULD MEAN HUESTIS ALSO HAS TO ADMIT THAT THE CONFIRMATION OF DR BECKS WORK PUBLISHED BY NIDA WAS IN ERROR?
http://www.drugabuse.gov/news-events/nida-notes/2014/05/device-detects-marijuana-in-breath-hours-after-smoking
NEXT THE STONER REPORTER STATES THAT
Back at the Marijuana Investor Summit, one of the weed world’s most respected watchdogs, Alan Brochstein, approached the Cannabix CFO, who was manning the booth while Mlait and Malhi were at lunch.
WHO ANOINTED THIS TWO BIT PAID PUMPER AS THE WORLD'S MOST RESPECTED WATCHDOG" .....A LITTLE BIAS BY THE STONER REPORTER AGAIN
READ THE ARTICLE WITH A VIEW TO ITS BIAS..I AM NOT BITING OFF THE HEADS THAT HAVE MADE ME MONEY TO THIS POINT BASED AN ARTICLE BY SOME UN- ACCREDITED STONER WRITER WHO HAS NO STANDING IN THE INVESTMENT COMMUNITY OR THE JOURNALISM WORLD
http://bitterempire.com/in-which-we-eviscerate-that-stupid-buzzfeed-article-on-cannabis-concentrates/
Writing about weed is not difficult. It’s an exciting topic that appeals to a broad (and growing) audience of people. The slow end to prohibition has been a godsend to lazy writers, who have discovered that any piece on cannabis culture intersecting with mainstream society can generate thousands of page views regardless of the quality of the piece’s reporting or analysis. To those of us on the front lines of the drug war, cutesy articles on weed yoga or whatever are a bit of a double-edged sword. These pieces help normalize weed, which is an essential facet of political organizing, so it’s easy to forgive their frequent inaccuracies or hackish stereotyping of cannabis. But Buzzfeed’s horrendous article on concentrates is more than their usual mediocre click bait garbage. It’s journalistic malpractice.
Marylin Huestis? Did she just blame Dr Olof Beck of publishing false reports? Heres her articles and the work the National Insititue of Drug Abuse published confirming Dr. Becks work? I question the Buzzed credibility against medically published documents
http://www.drugabuse.gov/news-events/nida-notes/2014/05/device-detects-marijuana-in-breath-hours-after-smoking
Device Detects Marijuana in Breath Hours After Smoking
May 29, 2014
The picture shows a person breathing into a hand-held Breathalyzer-type breath-collection device. The device contains a small filter pad, which captures exhaled compounds (such as marijuana metabolites). The pad is used in subsequent chemical analyses to determine concentrations of the captured breath compounds.Figure 1. A Simple Breath-Collection Device Can Be Used To Screen for Marijuana Use A subject breathes into a SensAbues collection device, which contains a polymeric filter pad to capture marijuana metabolites, including THC. The metabolites are extracted from the pad and detected via mass spectrometry.
Picture courtesy of http://sensabues.com
Breath expelled into a Breathalyzer-style collection device contained measurable amounts of marijuana’s main psychoactive ingredient, tetrahydrocannabinol (THC), for up to 2 hours after participants in a recent clinical trial smoked the drug. The finding by researchers at NIDA’s Intramural Research Program affirms that workplace and roadside breath testing for recent marijuana use is feasible in principle.
“Ours is the first basic research study using controlled administration of marijuana to determine if it is possible to detect metabolites in breath,” says study leader Sarah Himes, a doctoral candidate in toxicology and Intramural Research Training Award fellow at NIDA. Her positive result opens the way to further development of the marijuana breath-testing technique, which holds the potential to fulfill a public-safety need that has become increasingly pressing as marijuana use has risen and some jurisdictions have legalized use of the drug.
The Need for a Better Test
In a 2007 roadside survey conducted by the National Highway Traffic Safety Administration, 8.7 percent of weekend nighttime drivers tested positive for marijuana, 4 times as many as had blood alcohol concentrations exceeding the legal limit. “That was a wake-up call for the Nation,” says Dr. Marilyn Huestis, chief of the Chemistry and Drug Metabolism Section at NIDA and principal investigator on the study. “Marijuana negatively affects divided attention and executive function—brain functions that are needed for the complex behavior of driving,” she notes.
At present, authorities take people suspected of driving while impaired by marijuana or other drugs to a medical facility to have blood drawn and assayed. However, blood THC concentrations may be considerably lower by the time the blood is collected than when the person was behind the wheel. When fully developed, breath testing will avoid this problem: Authorities will be able to obtain breath samples, noninvasively as they do in alcohol testing, and interpret them on the spot.
Evidentiary Exhalation
Ms. Himes, working with Dr. Huestis and colleagues at NIDA’s Intramural Research Program (IRP), recruited 13 frequent and 11 occasional marijuana smokers for their study. The frequent users reported smoking the drug 4 or more times per week in the last 3 months, and the occasional users reported smoking less than twice weekly during that time. The researchers corroborated the participants’ self-reported use by measuring the concentrations of THC metabolites in their urine, saliva, and blood.
In the study, each participant smoked a single marijuana cigarette containing 6.8 percent THC, then provided breath samples at regular intervals using the SensAbues collection device (see Figure 1). The device, designed by study collaborator Dr. Olof Beck of Karolinska University Hospital in Stockholm, Sweden, traps cannabinoids on a polymeric filter pad. The IRP research team assayed the pads for THC using mass spectrometry.
Figure 2. The Marijuana Metabolite THC Is Detectable in Exhaled Breath Frequent and occasional marijuana smokers submitted positive breath tests for THC at roughly 1 half-hour and 1 hour after smoking a single marijuana cigarette, on average, respectively. Frequent smokers also tested positive 2 hours after smoking. SensAbues breath pads detected the presence of THC on pads containing as little as 50 picograms of the metabolite (dashed line).
Text Description of Graphic
The test results detected recent marijuana smoking in the initial breath samples from all the frequent users and all but one of the occasional users. The samples were obtained, on average, 0.9 hours after smoking. The percentage of breath samples testing positive for THC declined steadily in both groups as time passed, but did so more rapidly among the occasional smokers (see Figure 2). Among the frequent smokers, 77 percent of breath samples collected at 1.4 hours tested positive; 54 percent were positive at 2.4 hours; and zero at 3 hours. Among the occasional users, 64 percent were positive at 1.5 hours, and none at 2 hours. The frequent smokers’ median THC breath concentration was 94.8 picograms (pg) per pad, and the occasional users’ was 61.0 pg per pad.
The researchers also demonstrated that:
Their mass spectrometry assay was highly sensitive, detecting THC on SensAbues pads containing as little as 50 picograms of the drug.
THC was stable enough on the pads that reasonable delays in processing might not affect the usefulness of the results: When stored for 8 hours at room temperature, 72 hours at 4°C, or 6 months at -20°C, less than 20 percent of the drug was lost.
THC measurements were unaffected by the presence of 92 other drugs that drivers might co-ingest with marijuana, including common stimulants, such as caffeine or nicotine; painkillers, such as aspirin or acetaminophen; and illegal drugs.
Steps to Road Readiness
The IRP study demonstrates that breath testing can reliably reveal recent marijuana smoking. The researchers’ focus now turns to making breath testing practical for use on the Nation’s roads.
“Our method allows a window of detection of only 1 to 2 hours after smoking,” Ms. Himes says. “There’s still a lot of work to be done to improve sensitivity and increase detection at later time points.” Ideally, a roadside-testing device should reliably yield positive results for as long as a smoker’s driving remains impaired, or for at least 6 hours.
Two additional hurdles must be surmounted before breath testing for marijuana can become a useful tool for highway safety: determining the concentrations of THC that correspond to driving impairment, and developing equipment that will permit on-the-spot analysis of breath-testing results.
In response to the first of these challenges, the IRP researchers are planning studies in which participants will take simulated driving tests after smoking marijuana. The results will guide lawmakers in setting reasonable legal limits for drivers’ THC breath concentrations.
An issue that will need to be addressed in setting such limits is the difference, seen in the current study, between frequent and occasional marijuana smokers’ breath THC concentrations. The reason for the difference, Dr. Huestis explains, is that the two groups smoke the drug differently: “People control how much drug they put in their bodies by the depth of inhalation, how quickly they puff, the time between puffs, and exhalation time.” Occasional users probably do not take in as much drug from the cigarette as frequent users do, Dr. Huestis says, nor do they have as much buildup of THC in their systems. However, occasional users, having less tolerance for the drugs’ effects, may be impaired at lower concentrations.
Although the SensAbues breath-collection device fits easily into a glove compartment or a coat pocket, the liquid chromatography-coupled tandem mass spectrometer that the IRP team used to assay the breath pads is a large machine found only in laboratories. Its lack of portability might not pose an obstacle for drug testing in workplaces and other situations where results are not needed on the spot and samples can be mailed away to be assayed. However, for use in identifying drugged drivers, both the collection device and the analysis equipment must be small enough to be kept ready at hand.
“This is just the start,” says Dr. Huestis. “We were able to achieve beautiful sensitivity using our sophisticated lab equipment. The next step will be to find instrumentation that can be used at the roadside.” Dr. Huestis believes this can be done, and points, as an example, to the equipment used in airports to check for explosives—which in fact are much smaller versions of the instruments used in the study.
The SensAbues device is being evaluated elsewhere for potential use in detecting drugs including cocaine, methamphetamine, heroin, and benzodiazepines.
Source:
Himes, S.K.; Scheidweiler, K.B.; Beck, O.; Gorelick, D.A.; Desrosiers, N.A.; Huestis, M.A. Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clinical Chemistry. 59(12):1780-1789. 2013. Abstract
Tags
College Students
Fox News and Dr Goldberger--toxicologist and DUI expert
http://www.myfoxorlando.com/story/28986864/new-marijuana-breathalyzer-could-detect-drugged-drivers
Vantage does not have a device for detecting THC. They MAY HAVE a device for cancer detection but EVEN that is not verified.
The only thing Vantage has is a news release saying their BOD authorized the company to" Vantage mHealthcare Inc., (VNTH) ("Vantage") or (the "Company") today announced that its Board of Directors voted to develop a marijuana detection capability for its sensor"
The history of the ownership on Vantage Mhealth, it news releases can be determined with this article:
https://www.sec.gov/litigation/litreleases/2014/lr23052.htm
I think we bottomed last two weeks and made a solid base at .30 and are bouncing up from that. I bet we close at .375 today. Expect news before the Chicago conference and possible media stories that should come from Denver conference. Salmon mentored there was a media lady at the Cannabix booth.
Salmon do you know if she was going to write and who was she with?
I had bought 200K shares of VNTH over the past days but when I found the article and JeremyBarberas fraud charges relating to issuing false news releases in the past, it makes me question the release about the Vantage breathlalyzer. I am selling and moving on
I have confirmed that BLO had a provisional patent that has to be converted to full patent this month. With the Beta version they should e in good position to do so.
Provisonals are never published, they give the inventor 365 days to perfect the patent application and give him the filing date of the provisional as the first file date.
Senseabues patent is on this device. Madmax first tried to scare everyone by saying that major breathalyzer companies were secretly developing a thc breathalyzer and kill BLO.
Now he claims that a patent on a whistle like device somehow compares to what BLO has under development and that some announcements by a cash starved company to "look into" some technology is a big BLO to Cannabix.
Compare Senseabues patent and look at their product versus Cannabix
http://sensabues.com/product
SensAbues® collection kit. Easy to use with instructions included. After the collection the device is sealed and sent for laboratory analysis.
Madmax....can you tell us how many of these units these have sold and to whom? Also what is Senseabues cash position?
Cannabix devices is not a whistle and is fully funded thru development:
Senseabues has patent on a whistle like device that collects a sample that has to be sent to a lab for analysis
They also have zero cash and are private
Go to their website to see the whistle they have patented
Vantage M Health and its owners
I did some further DD on Vantage Health and found out that Jeremy Barbera owns the paren company which owns 140M shares in Vantage. Take a look at this history he has in the business and fraud charges for false news releases.
SEC
'Serial Con Man' Busted in Solar Energy Farm Scam
Dunstan PrialBy Dunstan PrialPublished July 29, 2014FOXBusiness
Facebook11 Twitter10 livefyre0 Email Print
solar plant, solar panel (REUTERS)
The Securities and Exchange Commission charged a jailed con man for the second time this month with luring investors into a phony venture using made-up press releases -- this time for a non-existent solar energy company.
Christopher Plummer is currently serving time in federal prison on unrelated felony fraud charges. According to the SEC, he allegedly touted a joint venture to develop and manage solar energy farms across the country on land purportedly owned by an electricity provider he operated.
The company's CEO J. Jeremy Barbera was also charged with fraud. In a statement, the SEC said both Barbera and Plummer issued press releases “falsely portraying” MSGI Technology Solutions as a successful renewable energy company on the brink of turning a profit.
But MSGI had no operations, customers, or revenue at the time the press releases were issued, and Plummer’s management company did not actually possess any of the assets or financing needed to develop the purported solar energy farms, the SEC said.
According to the SEC’s complaint filed in Manhattan federal court, in addition to co-authoring misleading press releases with Plummer, Barbera made other material misstatements about MSGI’s operations.
For example, he described MSGI in press releases and on the company's website as a functioning security company with customers all over the world. This, despite the fact MSGI lacked financial means to manufacture any security products on a commercial scale.
The SEC said Barbera also falsely claimed in press releases another sham entity operated by Plummer purchased MSGI’s large amount of outstanding debt. In addition, he's also said to have falsely touted nonexistent solar energy projects with an entity unrelated to Plummer.
Barbera and MSGI agreed to settle the SEC’s charges.
“It is vital that information disseminated by a company into the marketplace be corroborated and truthful,” Sanjay Wadhwa, senior associate director of the SEC’s New York Regional Office said. “Barbera caused MSGI to issue press releases baselessly touting nonexistent assets and phony business opportunities, which had the harmful effect of misleading investors.”
On July 18, the SEC charged Plummer with fraud in a similar incident. In that scheme, he and another purported CEO allegedly created press releases touting a supposedly-successful vaccine development company that was actually failing.
The SEC alleged in the earlier scheme Plummer joined forces with the CEO of CytoGenix, Lex M. Cowsert, and the two of them defrauded investors by making “extravagant claims” about the microcap company’s revenue and other benefits flowing from a "shared revenue agreement" with Franklin Power & Light, an electricity provider that Plummer supposedly operated.
In truth, Plummer's company was a “complete sham,” according to the SEC. CytoGenix had in fact lost all of its vaccine patents and other intellectual property in a lawsuit, and Plummer and Cowsert stole proceeds of CytoGenix stock offerings that they told investors would be used for energy production projects and other corporate purposes, the SEC said.
The SEC described Plummer as a “serial con man.” He is serving a multi-year federal prison term for an unrelated fraud and has two prior convictions for fraud offenses.
Senseabues is a whistle like tool that collects a sample to be sent to lab for analysis. It is not a breathalyzer.
Here is a picture: and their website
http://sensabues.com/product
http://sensabues.com/product
http://sensabues.com/wp-content/gallery/technology/funkar1.jpg
They collect a sample into a whistle like device and then send it to a lab for confirmation, which takes many weeks
Who owns Nanobeak? the parent of Vantage Health..its is listed a Jeremy Barbera in SEC filings.
The guy who owns all the stock in Vantage Health is Jeremy Barbera (he owns Nanobeak)
http://www.sec.gov/Archives/edgar/data/1591072/000149315214004199/0001493152-14-004199.txt
http://www.foxbusiness.com/economy-policy/2014/07/29/serial-con-man-busted-in-solar-energy-farm-scam/
Serial Con Man' Busted in Solar Energy Farm Scam
By Dunstan PrialPublished July 29, 2014FOXBusiness
Facebook11 Twitter10 livefyre Email Print
(REUTERS)
The Securities and Exchange Commission charged a jailed con man for the second time this month with luring investors into a phony venture using made-up press releases -- this time for a non-existent solar energy company.
Christopher Plummer is currently serving time in federal prison on unrelated felony fraud charges. According to the SEC, he allegedly touted a joint venture to develop and manage solar energy farms across the country on land purportedly owned by an electricity provider he operated.
The company's CEO J. Jeremy Barbera was also charged with fraud. In a statement, the SEC said both Barbera and Plummer issued press releases “falsely portraying” MSGI Technology Solutions as a successful renewable energy company on the brink of turning a profit.
But MSGI had no operations, customers, or revenue at the time the press releases were issued, and Plummer’s management company did not actually possess any of the assets or financing needed to develop the purported solar energy farms, the SEC said.
According to the SEC’s complaint filed in Manhattan federal court, in addition to co-authoring misleading press releases with Plummer, Barbera made other material misstatements about MSGI’s operations.
For example, he described MSGI in press releases and on the company's website as a functioning security company with customers all over the world. This, despite the fact MSGI lacked financial means to manufacture any security products on a commercial scale.
The SEC said Barbera also falsely claimed in press releases another sham entity operated by Plummer purchased MSGI’s large amount of outstanding debt. In addition, he's also said to have falsely touted nonexistent solar energy projects with an entity unrelated to Plummer.
Barbera and MSGI agreed to settle the SEC’s charges.
“It is vital that information disseminated by a company into the marketplace be corroborated and truthful,” Sanjay Wadhwa, senior associate director of the SEC’s New York Regional Office said. “Barbera caused MSGI to issue press releases baselessly touting nonexistent assets and phony business opportunities, which had the harmful effect of misleading investors.”
On July 18, the SEC charged Plummer with fraud in a similar incident. In that scheme, he and another purported CEO allegedly created press releases touting a supposedly-successful vaccine development company that was actually failing.
The SEC alleged in the earlier scheme Plummer joined forces with the CEO of CytoGenix, Lex M. Cowsert, and the two of them defrauded investors by making “extravagant claims” about the microcap company’s revenue and other benefits flowing from a "shared revenue agreement" with Franklin Power & Light, an electricity provider that Plummer supposedly operated.
In truth, Plummer's company was a “complete sham,” according to the SEC. CytoGenix had in fact lost all of its vaccine patents and other intellectual property in a lawsuit, and Plummer and Cowsert stole proceeds of CytoGenix stock offerings that they told investors would be used for energy production projects and other corporate purposes, the SEC said.
The SEC described Plummer as a “serial con man.” He is serving a multi-year federal prison term for an unrelated fraud and has two prior convictions for fraud offenses.
How does VNTH plan to operate with a negative cash balance.
They also don't have a phone number to call them at and the number they list on their news releases goes to voicemail and is never returned.
They have over 200M shares out- zero cash and allot media stories and public stats on their website...very little about what they have developed or are developing
Their last news release said their are going to "look" into a marijuana breathalyzer...with their cash position, that is all they can do....look at it.
It appears to be atypical zero cash, lots of shares out OTC pump and dump.
Is there a credible person behind this. there website does not even list who the management is
Running two companies
Many Junior listed CEO's operate more then one company. Take a look at the top two traders on the TSX_V for the last month. V.CVX and V.PHM Both companies are in the heatlh care field and founded and operated by
Michael Dalsin - Chairman and CEO: Chairman and Former CEO of Patient Home Monitoring (TSXV:PHM), former Managing Director of Stanmore Capital Partners, a healthcare services investment group founded in 2002. Previous to Stanmore, Mr. Dalsin worked in international investment banking and deal-making in London, Hong Kong and New York. He has participated as a lead banker and negotiator for a number of small and medium market ($25M to $100M) international roll-ups for both American and English companies. He holds an economics degree from University of Wisconsin - Madison.
V.PHM just raised close to $60M
Rolling Up U.S. Healthcare Companies Providing Services to Patients with Chronic Disease
PHM is currently a positive cash flow and profitable company servicing patients with chronic heart disease and will act as a platform for acquisitions.
PHM is focused on a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity. Because of the new and highly fragmented nature of the market, PHM is actively working to identify and evaluate profitable, annuity-based companies to acquire their patient databases and technical expertise at favorable prices.
PHM's post acquisition organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient. The expected result is growing EPS with each acquisition and growing revenue and profits from the cross selling efforts.
================================================
V.CVX Just raised $17M in bout deal from FUNDS
Rolling Up Addiction Treatment Centers in the U.S.
Convalo is focused on a highly fragmented and fast growing market of small privately-held companies servicing patients with various types of addictions, such as substance abuse. The fast growth of the industry was triggered by the recent regulations in the US, including ObamaCare and the Parity Act, that require private health insurance companies to treat many mental health disorders on parity with physical disorders. The provision in ObamaCare giving parents the option to cover children until age 26 expands the universe of those who can be treated. Health insurance companies are motivated to reduce treatment costs by sending patients away from often extraordinarily expensive residential treatment centers to more affordable outpatient centers - the portion of the market that Convalo will serve.
Convalo’s strategy is to continue to consolidate specific sectors of the addiction treatment market in major cities across the US. Many of these companies are currently owned or managed by individual therapists who try to run them as an adjunct to their private practice, with limited marketing efforts.
Convalo’s first acquisition, BLVD Treatment Centers, is located in West Hollywood and has seen its revenue increased by 200% within 6 months due to three factors:
PHM trades at over $1.5 and Convalo has gone from $.20 to he $.70 range. Both companies have raised funds from sophisiticated investors who recognize business opportunities when they arise. It think it goes well that management for BLO management has the ability to raise funds for their ventures and that BLO is not diluted into multiple projects and stays committed to their Breathalyzer. As far as I know BLO is not financially involved with any other ventures and is 100% committed to its breathalyzer deveopment
Dr. Marilyn Huestis
Dr. Huestis reported that although roadside saliva testing has been used in Europe and Australia and has been approved in several states in the United States, THC can be detected for up to 48 hours in oral fluid. This means its detection may not coincide with impairment.
On the other hand, she noted that noninvasive breath alcohol tests are widely used by law enforcement. "Everyone would love it if we could have a breath test like we have for alcohol," she said.
Saliva test are not favoured by prosecutors, officers or science
http://www.medscape.com/viewarticle/815396
A new breath test may help in screening drivers or even employees for recent marijuana use, preliminary research suggests.
A small pilot study of 25 adult long-term or occasional smokers used a new test that detects the presence of delta-9-tetrahydrocannabinol (THC), the main psychoactive chemical in marijuana, in the breath of those who used the substance within 30 minutes to 2.5 hours prior.
"The whole issue of drugged driving is key right now," senior author Marilyn A. Huestis, PhD, chief of chemistry and drug metabolism at the Intramural Research Program at the National Institute on Drug Abuse (NIDA) and adjunct professor at the University of Maryland in Baltimore, told Medscape Medical News.
"In fact, the Office of National Control Policy has made the reduction of drugged driving 1 of their top 3 initiatives for the last several years. It's a really big health and safety problem," she said.
However, she noted that when it comes to the study's findings, more work needs to be done.
"This is very interesting and exciting, but we have a lot of science to develop before this type of test can end up by the roadside. We need to find out about how drugs get into breath, how long they're in there, and then we have to develop the methods that could then be used in the field," said Dr. Huestis.
"It's a ways off, but it's a big step forward," she added.
The study was published online in Clinical Chemistry.
More Teens Driving High
A recent study published in the American Journal of Public Health and reported by Medscape Medical News showed that more teens are now driving while high, and another study showed that drivers who consumed cannabis within 3 hours of driving were twice as likely to cause a serious road accident as those who did not use the substance.
However, in an editorial that accompanied the latter study, Wayne Hall, PhD, from the University of Queensland in Australia, noted that public health education about these dangers are probably not enough to deter cannabis users from driving.
"They will also need to be persuaded that they are at risk of their cannabis use being detected," he wrote.
Dr. Marilyn Huestis
Dr. Huestis reported that although roadside saliva testing has been used in Europe and Australia and has been approved in several states in the United States, THC can be detected for up to 48 hours in oral fluid. This means its detection may not coincide with impairment.
On the other hand, she noted that noninvasive breath alcohol tests are widely used by law enforcement. "Everyone would love it if we could have a breath test like we have for alcohol," she said.
In the current study, the investigators enrolled 13 long-term marijuana smokers (partaking more than 4 times per week, on average) and 11 occasional smokers (partaking fewer than 2 times per week).
1 of 2
Strong cash position for BLO
BLO has a strong cash position as the last year of operations has largely been funded by the exercise of warrants that were issued to a private company that vended the technology to BLO. Malhi is a director of the private company and has been exercising the warrants and reporting the sales as "indirect sales"
His exercise of warrants and exercise of warrants by other shareholders has largely funded last years operations and left BLO with close to $1M in the treasury. Malhi states he has not sold any shares personally
Marijuana Impaired Driving article
http://epirev.oxfordjournals.org/content/early/2011/10/04/epirev.mxr017.full
Since 1996, 16 states and the District of Columbia in the United States have enacted legislation to decriminalize marijuana for medical use. Although marijuana is the most commonly detected nonalcohol drug in drivers, its role in crash causation remains unsettled. To assess the association between marijuana use and crash risk, the authors performed a meta-analysis of 9 epidemiologic studies published in English in the past 2 decades identified through a systematic search of bibliographic databases. Estimated odds ratios relating marijuana use to crash risk reported in these studies ranged from 0.85 to 7.16. Pooled analysis based on the random-effects model yielded a summary odds ratio of 2.66 (95% confidence interval: 2.07, 3.41). Analysis of individual studies indicated that the heightened risk of crash involvement associated with marijuana use persisted after adjustment for confounding variables and that the risk of crash involvement increased in a dose-response fashion with the concentration of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol detected in the urine and the frequency of self-reported marijuana use. The results of this meta-analysis suggest that marijuana use by drivers is associated with a significantly increased risk of being involved in motor vehicle crashes.
12 Marijuana stocks to avoid Seeking Alpha
http://m.seekingalpha.com/article/2930326-12-more-marijuana-stocks-to-avoid-part-i
Feel free to share this on other marijuana stock talks
Edibles are detected.
Once eaten, THC makes its way from the blood stream and into the Lungs where it is eliminated. THC gets eliminated thru the lungs and Cannabinoids remain in your blood and fast cells and can turn positive on urine and saliva tests for several days.
Breath test is non invasive and accepted in North America as a cost of driving privileges. Blood and urine tests are very invasive and not accepted as a norm on the roads. They are only used in extreme cases of serious injuries or death
>25 threshold broken this week. Will we see $.30 next week. I expect %.75 when the prototype is revealed but that only my opinion. This is an amazing product and the right time. Ask a police officer what they think about this and you will get 110% endorsement.
Ask an investor and this is the best way to invest in the legalization of marijuana....companies that are applying to grow it are limited in how much revenue they can generate...this device is unlimited in its potential
Congrats to all the shareholders of Cannabix. Its am amazingly fitting story for this time in the marijuana cycle of society's acceptance of this drug and law enforcement's need for an tool to enforce it. I think this story will get major attraction as the product is revealed.
Apple at $125++++ next week with closer to $175 by year end. Great stock to hold but also trade.
Anyone notice how this stock opens high and then drops between 635MA PST and 705PM PST then bounces up. I have made that trade several trades now and it seems to have a pattern of opening high then dropping.
For high risk investors, I have a very unique investment in a company that is developing a marijuana breathalyzer to test drivers for marijuana impairment. Check them out at their website and do you own DD before investing. Its a penny stock but if they get it right it could explode BLOZF.
http://www.cannabixtechnologies.com/media-relations.
htmlhttp://www.ctvnews.ca/canada/thc-
breathalyzer-could-help-police-detect-stoned-drivers-1.1927203#ixzz38PCzOaNb
http://www.ctvnews.ca/canada/thc-breathalyzer-could-help-police-detect-stoned-drivers-1.1927203#ixzz38PCzOaNb
Apple at $125++++ next week with closer to $175 by year end. Great stock to hold but also trade.
Anyone notice how this stock opens high and then drops between 635MA PST and 705PM PST then bounces up. I have made that trade several trades now and it seems to have a pattern of opening high then dropping.
For high risk investors, I have a very unique investment in a company that is developing a marijuana breathalyzer to test drivers for marijuana impairment. Check them out at their website and do you own DD before investing. Its a penny stock but if they get it right it could explode BLOZF.
http://www.cannabixtechnologies.com/media-relations.
htmlhttp://www.ctvnews.ca/canada/thc-
breathalyzer-could-help-police-detect-stoned-drivers-1.1927203#ixzz38PCzOaNb
http://www.ctvnews.ca/canada/thc-breathalyzer-could-help-police-detect-stoned-drivers-1.1927203#ixzz38PCzOaNb